Chest ACCP Career Connection
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Guest Access | Sign In via User Name/Password
This Article
Right arrow Full Text (PDF) Free
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Article Archive
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Browne, R. J.
Right arrow Articles by Khoury, M. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Browne, R. J.
Right arrow Articles by Khoury, M. J.
(Chest. 1996;110:78-83.)
© 1996 American College of Chest Physicians

Alpha1-Antitrypsin Deficiency Deaths in the United States From 1979-1991

An Analysis Using Multiple-Cause Mortality Data

Rozalinde J. Browne BS1; David M. Mannino III MD1; and Muin J. Khoury MD, PhD2

1 From the Air Pollution and Respiratory Health Branch, Division of Environmental Hazards and Health Effects, National Center for Environmental Health, Centers for Disease Control and Prevention (CDC), Atlanta
2 From the Birth Defects and Genetic Diseases Branch, Division of Birth Defects and Developmental Disabilities, National Center for Environmental Health, Centers for Disease Control and Prevention (CDC), Atlanta

Objective: To describe trends of reported agr1-antitrypsin deficiency mortality in the United States from 1979-1991.

Methods: We analyzed death certificate reports in the multiple-cause mortality files compiled by the National Center for Health Statistics.

Results: Of the 26,866,600 deaths that occurred during the 13-year period, 1,930 had agr1-antitrypsin deficiency listed as a cause of death. Over this period, we would have expected 5,400 to 13,400 persons with this condition to die. The age-adjusted mortality rate with reported agr1-antitrypsin deficiency listed increased 86%, from 4.3 per 10 million in 1979 to 8.0 per 10 million in 1991. agr1-Antitrypsin deficiency mortality rates were higher among whites than among blacks or persons of other races. agr1-Antitrypsin deficiency was listed in 2.7% of all deaths with obstructive lung disease among persons aged 35-44 years old and in 1.2% of all deaths listing hepatic disease among children aged 1 to 14 years old.

Conclusions: agr1-Antitrypsin deficiency is an important risk factor for obstructive lung disease and hepatic disease in the United States, and it was reported with increasing frequency through the study period, although it is still likely underreported.

Key Words: agr1-antitrypsin • epidemiology • hepatic disease • mortality • obstructive lung disease

Submitted on September 26, 1995
Accepted on February 12, 1996




This article has been cited by other articles:


Home page
 Am. J. Respir. Crit. Care Med.Home page
American Thoracic Society/European Respiratory Society Statement: Standards for the Diagnosis and Management of Individuals with Alpha-1 Antitrypsin Deficiency
Am. J. Respir. Crit. Care Med., October 1, 2003; 168(7): 818 - 900.
[Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1996 by the American College of Chest Physicians.